ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
| Source: Oculis Holding AG
ZUG, Switzerland, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.
Attachment
ZUG, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) -- PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic...
Read MorePRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...
Read More